# A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)

> **NCT06072430** · PHASE3 · RECRUITING · sponsor: **Vivacelle Bio** · enrollment: 46 (estimated)

## Conditions studied

- Septic Shock
- Sepsis
- Hypovolemia

## Interventions

- **DRUG:** VBI-S

## Key facts

- **NCT ID:** NCT06072430
- **Lead sponsor:** Vivacelle Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-06
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2025-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06072430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06072430, "A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06072430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*